Senate HELP Hearing Focuses On WEN, High-Profile Cosmetic Safety Issues
This article was originally published in The Rose Sheet
Senate Health, Education, Labor and Pensions Committee members used the hearing as an opportunity to gain insight into current safety-assurance practices in the cosmetics industry, with national news issues such as WEN and Brazilian Blowout providing the backdrop.
You may also be interested in...
The New Jersey Democrat introduced multiple cosmetics-related amendments during the House Health Subcommittee's markup of draft OTC monograph reform legislation. While ultimately nothing came of the proposed measures, it's clear that Pallone remains intent on updating cosmetics regulations to require facility registration, adverse event reporting and good manufacturing practices, among other aims.
Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.
CFSAN Director Susan Mayne and other high-level FDA officials met with Guthy-Renker and WEN leadership and outside attorneys in September. The substance of the meeting is being kept under wraps, but it shows FDA’s continued involvement in the WEN issue, which drove discussion at the recent Senate HELP Committee hearing on cosmetics.